<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T18:46:18Z</responseDate>
  <request identifier="oai:figshare.com:article/33870565" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33870565</identifier>
        <datestamp>2026-09-17T04:26:41Z</datestamp>
        <setSpec>category_427</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 1_Changes in drug-use behaviors among people who use drugs with comorbid psychiatric disorders across the COVID-19 pandemic: a three-phase longitudinal cohort study.docx</dc:title>
          <dc:creator>Albert Kar Kin Chung (15196982)</dc:creator>
          <dc:creator>Johnson Kai Chun Law (23641588)</dc:creator>
          <dc:creator>Sau Wan Tang (23641579)</dc:creator>
          <dc:creator>Cheuk Yin Tse (23641582)</dc:creator>
          <dc:creator>Jerome Jun Hao Chen (25001383)</dc:creator>
          <dc:subject>Public Health and Health Services not elsewhere classified</dc:subject>
          <dc:subject>comorbid psychiatric disorders</dc:subject>
          <dc:subject>COVID-19</dc:subject>
          <dc:subject>drug-use behaviors</dc:subject>
          <dc:subject>substance misuse</dc:subject>
          <dc:subject>substance use disorder</dc:subject>
          <dc:description>Introduction&lt;p&gt;The COVID-19 pandemic substantially affected people who use drugs (PWUD) with comorbid psychiatric disorders. Lockdowns, shifts in drug markets, and fear of infection may have altered drug-use patterns. This prospective study examined changes in drug-use behaviors among PWUD with comorbid psychiatric disorders and identified factors associated with these changes across three distinct phases of the COVID-19 pandemic.&lt;/p&gt;Methods&lt;p&gt;A cohort of adult PWUD with ICD-10-defined comorbid psychiatric disorders was followed longitudinally from March 2021 to January 2024. Drug-use behaviors were assessed at three time points: during the active COVID-19 pandemic period, after receipt of at least two doses of a World Health Organization (WHO)-endorsed COVID-19 vaccine, and after the WHO declared the end of the global pandemic. Structured interviews and standardized rating scales were used to assess demographic characteristics, ICD-10 comorbid psychiatric disorders, drug-use behaviors, DSM-5 substance use disorder severity, and psychological dependence. COVID-19 infection history and vaccination status were verified through centralized electronic health records. Within-person changes in drug-use behaviors across time points and factors associated with these changes were examined using mixed-effects models.&lt;/p&gt;Results&lt;p&gt;One hundred and thirty participants (mean age 40.03 years) completed the study. The majority (62.3%) had a comorbid substance-induced psychotic disorder. Overall, 27.7% had laboratory-confirmed COVID-19 infection during the study period. Across the three phases, participants demonstrated significant reductions in substance use disorder severity and drug-use frequency. Sharing of drug-use equipment also declined and remained lower after the pandemic. Greater worry about contracting COVID-19 was associated with increased avoidance of drug use with others and reduced sharing of drug-use equipment. Prior COVID-19 infection was associated with lower drug-use frequency. Among individual drugs, cough syrup was uniquely linked to more frequent use, less solitary use, and sustained reductions in equipment sharing.&lt;/p&gt;Conclusion&lt;p&gt;Adult PWUD with comorbid psychiatric disorders demonstrated sustained improvements in drug-use behaviors throughout the COVID-19 pandemic and after its official conclusion. Both prior COVID-19 infection and greater worry about contracting COVID-19 were associated with these positive behavioral changes.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-17T04:26:41Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fpubh.2026.1878232.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_1_Changes_in_drug-use_behaviors_among_people_who_use_drugs_with_comorbid_psychiatric_disorders_across_the_COVID-19_pandemic_a_three-phase_longitudinal_cohort_study_docx/33870565</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
